N@N

MedaSorb Technologies Corporation: MedaSorb Technologies' Board Member, Edward Jones M.D., Elected President of the Renal Physi

^{Published on 2008-11-26 11:06:38 - Market Wire}
 

MONMOUTH JUNCTION, NJ--(Marketwire - November 26, 2008) - MedaSorb Technologies Corporation (OTCBB: [ MSBT ]) is pleased to recognize the election of its Director, Edward Jones M.D. to President of the Renal Physicians Association. Dr. Jones is an attending physician at Albert Einstein Medical Center and Chestnut Hill Hospital as well as Clinical Professor of Medicine at Temple University Hospital. Dr. Jones is currently president elect and will officially take over as president in 2009.

Dr. Jones is certified by the American Board of Internal Medicine. He is a practicing Nephrologist as well as medical director of a dialysis facility for Fresenius Medical Care. He teaches renal pathophysiology at Temple Hospital and at the Philadelphia College of Osteopathic Medicine.

Dr. Jones has served on the Board of Directors of MedaSorb for the past 2 years. Al Kraus President and CEO of MedaSorb said, "It does not surprise me that Dr. Jones was elected by his peers. He is an outstanding physician and is dedicated to improving patient care." On behalf of the Directors of MedaSorb we congratulate him for achieving such a distinguished honor from his peers.

About MedaSorb:

MedaSorb Technologies Corporation is a medical device company headquartered in Monmouth Junction, New Jersey. MedaSorb, through its wholly owned subsidiary, CytoSorbents, Inc., has developed and is preparing to commercialize a blood purification technology that efficiently removes toxic compounds from circulating blood.

CytoSorbents' initial products (CytoSorb™ and BetaSorb™) are known medically as hemoperfusion devices and incorporate proprietary adsorbent polymer technology. During hemoperfusion, blood is removed from the body via a catheter or other blood access device, perfused through a filter medium where toxic compounds are removed, and returned to the body. The CytoSorb™ device consists of a cylinder containing the adsorbent polymer beads. As blood passes over the beads in the cylinder, toxins (cytokines) are adsorbed from the blood. MedaSorb believes that potential healthcare applications for its products include: adjunctive treatment and/or prevention of sepsis, prevention of damage to organs donated for transplant prior to organ harvest, prevention of post-operative complications of cardiac surgery, short and long-term treatment of kidney failure, and drug detoxification.

MedaSorb's management team is led by Al Kraus, President and CEO, who has more than twenty-five years' experience managing companies in the dialysis, medical device products, personal computer and custom software industries. Other members of MedaSorb's management team include Vincent Capponi, COO, David Lamadrid, CFO, and James Winchester, MD, CMO.

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release are not promises or guarantees and are subject to risks and uncertainties that could cause our actual results to differ materially from those anticipated. These statements are based on management's current expectations and assumptions and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements. Actual results may differ materially from those expressed or implied by the statements herein. MedaSorb Technologies Corporation believes that its primary risk factors include, but are not limited to: obtaining government approvals including required FDA approvals; ability to successfully develop commercial operations; dependence on key personnel; acceptance of the Company's medical devices in the marketplace; the outcome of pending and potential litigation; compliance with governmental regulations; reliance on research and testing facilities of various universities and institutions; the ability to obtain adequate financing in the future when needed; product liability risks; limited manufacturing experience; limited marketing, sales and distribution experience; market acceptance of the Company's products; competition; unexpected changes in technologies and technological advances; and other factors detailed in the Company's Form 10-KSB filed with the SEC on April 15, 2008, which is available at [ http://www.sec.gov ].